Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 shares of Opus Genetics, Inc. at $4.96 for −$2.76M on Sep 30, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$2,755,980.80Shares × reported price
Shares traded
556,000Common Stock
Price per share
$4.96Reported price. Read footnotes for ranges.
% of reported position traded
14.66%This security and ownership context
Holdings after
3,236,171Direct
Trade date
Sep 30, 2026Sell
Filed
Oct 2, 2026, 7:47 PM ET2-day reporting delay
Accession
0002042266-26-000002Code S · Transaction 236035
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 3,792,171 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

IRD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IRD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −21%1w ago +5.5%1d ago +8.3%
Returns since7d +1.5%30d −20%90d180d1y

Footnotes in full

F1: This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.